2020
DOI: 10.3389/fonc.2020.00923
|View full text |Cite
|
Sign up to set email alerts
|

Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases

Abstract: Introduction: Childhood acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the acquisition of several genetic lesions in the lymphoid progenitors with subsequent proliferation advantage and lack of maturation. Along the years, it has been repeatedly shown that minimal residual disease (MRD) plays an important role in prognosis and therapy choice. The aim of the current study was to determine the prognostic role of MRD in childhood ALL patients in conjunction with other r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 16 publications
(10 citation statements)
references
References 19 publications
0
8
2
Order By: Relevance
“…The chemotherapeutic drug classes and the composition of the chemotherapy protocol at each time period were essentially the same for both regimens, i.e., diagnosis and assessment of sensitivity after 7 days of pretreatment with prednisone upon enrollment, continued initiation of VDLD (vincristine+dexamethasone+ L-asparaginase+daunorubicin) induced remission therapy, early intensive CAM (cyclophosphamide+cytarabine+6-mercaptopurine), mM (high-dose methotrexate + 6-mercaptopurine, or HR-1, HR-2, HR-3 all in two rounds), delayed intensive VDLD, CAM regimen (with 8 weeks of maintenance chemotherapy in between) in one or two rounds, and finally maintenance chemotherapy and regular intrathecal injections, with specific drug doses and risk assessment indicators in Ref ( 11 , 12 ).…”
Section: Methodsmentioning
confidence: 99%
“…The chemotherapeutic drug classes and the composition of the chemotherapy protocol at each time period were essentially the same for both regimens, i.e., diagnosis and assessment of sensitivity after 7 days of pretreatment with prednisone upon enrollment, continued initiation of VDLD (vincristine+dexamethasone+ L-asparaginase+daunorubicin) induced remission therapy, early intensive CAM (cyclophosphamide+cytarabine+6-mercaptopurine), mM (high-dose methotrexate + 6-mercaptopurine, or HR-1, HR-2, HR-3 all in two rounds), delayed intensive VDLD, CAM regimen (with 8 weeks of maintenance chemotherapy in between) in one or two rounds, and finally maintenance chemotherapy and regular intrathecal injections, with specific drug doses and risk assessment indicators in Ref ( 11 , 12 ).…”
Section: Methodsmentioning
confidence: 99%
“…The South China Children’s Leukemia Group (SCCLG)-ALL-2016 is a prospective, multi-institutional clinical trial involving 18 major hospitals/medical centers ( 9 , 10 ). We designed the SCCLG-ALL-2016 collaborative protocol based on the backbones of Berlin-Frankfurt-Münster (BFM) ALL-IC-2009 and Guangdong (GD)-2008-ALL ( 11 , 12 ). In this study, we aimed to determine the impact of CNSL at diagnosis on the clinical outcomes of childhood B-cell ALL in the SCCLG-ALL-2016 trial.…”
Section: Introductionmentioning
confidence: 99%
“…We excluded patients of the Flow Low-risk (FLR) category because exact ratio of FXIII-A positive lymphoblasts below 0.1% could not be estimated due to the cytoplasmic expression of FXIII-A. The percentage of FXIII-A positive leukemic lymphoblasts of patients with Flow Medium-risk (FMR) and Flow High-risk (FHR) categories was significantly lower in Day 15 than in Day 0 samples (p < 0.001) [14]. FXIII-A expression of FXIII-A negative de novo cases did not change significantly by Day 15.…”
Section: Figurementioning
confidence: 99%
“…The consortium developed a multiparameter FC-based MRD detection method as a pilot project of ALL IC-BFM 2002 [13]. Result of mid-induction, day 15 bone marrow (BM) FC-MRD was incorporated in the risk assessment approach of the next ALLIC clinical trial, ALL IC-BFM 2009 (EuDract: 2010-019722-13, unpublished data) [14]. ALLIC FC laboratories became members of the International BFM Flow-network [8,15].…”
Section: Introductionmentioning
confidence: 99%